cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Agenus Inc
40 own
69 watching
Current Price
$1.45
$0.04
(2.84%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
495.41M
52-Week High
52-Week High
3.37
52-Week Low
52-Week Low
1.25
Average Volume
Average Volume
3.2M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization495.41M
icon52-Week High3.37
icon52-Week Low1.25
iconAverage Volume3.2M
iconDividend Yield--
iconP/E Ratio--
What does the Agenus Inc do?
Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, and LAG-3. In addition, the company develops vaccine programs, such as Prophage cancer vaccine candidate; AutoSynVax, a synthetic cancer vaccine program targeting the neo-epitope landscape in cancer patients; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a novel class of tumor specific neo-epitopes. Further, Agenus Inc. develops QS-21 Stimulon, a saponin-based vaccine adjuvant that has completed Phase III clinical trials for the treatment of malaria and shingles. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Read More
News & Events about Agenus Inc.
Business Wire
26days ago
Agenus (Nasdaq: AGEN), a leading immuno-oncology company dedicated to developing innovative treatments for cancer and infectious diseases, today announced a data update on botensilimab (multifunctional CTLA-4 antibody) in combination with balstilimab (PD-1 antibody) for patients with...
Zolmax
1month ago
Shares of Agenus Inc. (NASDAQ:AGEN Get Rating) have earned an average rating of Moderate Buy from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average ...
Business Wire
1month ago
Agenus (Nasdaq: AGEN), a leading immuno-oncology company specializing in immunological agents for cancer and infectious diseases, today announced plans to present clinical data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, to be held June 2-6 in Chicago, IL. Data from a...
Zolmax
1month ago
Agenus (NASDAQ:AGEN Get Rating)s stock had its buy rating reaffirmed by investment analysts at B. Riley in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $8.00 price target on the biotechnology companys ...
Business Wire
2 months ago
Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced results from a cohort of 24 evaluable patients in an expansion of the Companys Phase 1b study of botensilimab (multifunctional CTLA-4 antibody) in...
Frequently Asked Questions
Frequently Asked Questions
What is Agenus Inc share price today?
plus_minus_icon
Can Indians buy Agenus Inc shares?
plus_minus_icon
How can I buy Agenus Inc shares from India?
plus_minus_icon
Can Fractional shares of Agenus Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Agenus Inc stocks?
plus_minus_icon
What is today’s traded volume of Agenus Inc?
plus_minus_icon
What is today’s market capitalisation of Agenus Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Agenus Inc?
plus_minus_icon
What percentage is Agenus Inc down from its 52-Week High?
plus_minus_icon
What percentage is Agenus Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.45
$0.04
(2.84%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00